Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Los Angeles, California 90095


RATIONALE: Modafinil may be effective in relieving fatigue and improving behavioral changes such as memory loss in patients who have undergone treatment for primary brain cancer. The effectiveness of modafinil in relieving fatigue and improving behavioral change is not yet known. PURPOSE: This randomized clinical trial is comparing how well two different doses of modafinil work in treating fatigue and behavioral changes in patients who have undergone treatment for primary brain cancer.

Study summary:

OBJECTIVES: - Compare the effectiveness of low-dose vs high-dose modafinil for treatment of fatigue and neurobehavioral dysfunction in patients with primary brain tumors. - Determine the safety of this drug in these patients. - Compare quality of life of patients treated with 2 different doses of this drug. OUTLINE: This is a randomized, double-blind, parallel-group study. Patients are randomized to 1 of 2 arms. - Randomized phase: - Arm I: Patients receive oral high-dose modafinil twice daily. - Arm II: Patients receive oral low-dose modafinil twice daily. In both arms, treatment in this phase continues for 3 weeks followed by a 1-week washout period. - Extended treatment phase:After the 1-week washout period, all patients receive oral low-dose modafinil once daily on days 1-3. The dose is then titrated to an optimal level and administered in divided doses. Fatigue, neurobehavioral dysfunction, and quality of life are assessed during the randomized phase at baseline and on days 7 and 21 and then during the extended treatment phase at baseline and on days 28 and 56. PROJECTED ACCRUAL: Approximately 30 patients will be accrued for this study.


Inclusion Criteria: - Diagnosis of primary malignant brain tumor and receiving treatment in the UCLA Neuro-Oncology Program - Nonmalignant cerebral tumors also allowed - Received some combination of prior therapy for disease, including neurosurgical resection, radiotherapy, and cytotoxic or cytostatic chemotherapy - Mild to severe fatigue and/or attention/memory impairment, as measured by the Clinical Global Impression of Severity Scale - Age 21 to 65 - Able to speak English - Capable of completing self-rating scales and one-on-one psychometric tests - Negative pregnancy test - Fertile patients must use effective contraception - Concurrent conventional chemotherapy (e.g., carboplatin, lomustine, temozolomide) allowed - Concurrent glucocorticoids (e.g., dexamethasone) allowed - Concurrent tamoxifen allowed - At least 30 days since prior stimulants (e.g., amphetamines or methylphenidate) - Concurrent anticonvulsants allowed - Concurrent isotretinoin allowed Exclusion Criteria: - Have significant hepatic disease, defined as SGOT greater than or equal to 2.5 times the upper limit of normal. - Have significant renal disease, defined as creatinine greater than or equal to 1.5mg/dl. - severe cognitive impairment - other terminal illness - emergency patient - institutional resident - prisoner or parolee - UCLA students or staff - pregnant or nursing - concurrent irinotecan - concurrent participation in UCLA experimental chemotherapy trials - prior modafinil - concurrent experimental anticancer medication - concurrent tricyclic antidepressants and/or monoamine oxidase inhibitors



Primary Contact:

Principal Investigator
Timothy F. Cloughesy, MD
Jonsson Comprehensive Cancer Center

Backup Contact:


Location Contact:

Los Angeles, California 90095
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: October 09, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.